BioVie Statistics
Total Valuation
BioVie has a market cap or net worth of $23.58 million. The enterprise value is $1.65 million.
| Market Cap | 23.58M |
| Enterprise Value | 1.65M |
Important Dates
The next estimated earnings date is Wednesday, August 14, 2024, after market close.
| Earnings Date | Aug 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
BioVie has 61.17 million shares outstanding. The number of shares has increased by 26.82% in one year.
| Shares Outstanding | 61.17M |
| Shares Change (YoY) | +26.82% |
| Shares Change (QoQ) | +17.37% |
| Owned by Insiders (%) | 39.63% |
| Owned by Institutions (%) | 12.01% |
| Float | 36.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.25 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.45, with a Debt / Equity ratio of 0.44.
| Current Ratio | 2.45 |
| Quick Ratio | n/a |
| Debt / Equity | 0.44 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -9.19 |
Financial Efficiency
Return on equity (ROE) is -301.60% and return on invested capital (ROIC) is -140.32%.
| Return on Equity (ROE) | -301.60% |
| Return on Assets (ROA) | -132.60% |
| Return on Capital (ROIC) | -140.32% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.07M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -92.51% in the last 52 weeks. The beta is 1.18, so BioVie's price volatility has been higher than the market average.
| Beta (5Y) | 1.18 |
| 52-Week Price Change | -92.51% |
| 50-Day Moving Average | 0.46 |
| 200-Day Moving Average | 1.42 |
| Relative Strength Index (RSI) | 37.88 |
| Average Volume (20 Days) | 512,290 |
Short Selling Information
The latest short interest is 1.40 million, so 2.29% of the outstanding shares have been sold short.
| Short Interest | 1.40M |
| Short Previous Month | 1.13M |
| Short % of Shares Out | 2.29% |
| Short % of Float | 3.80% |
| Short Ratio (days to cover) | 2.41 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.37M |
| Pretax Income | -36.29M |
| Net Income | -37.18M |
| EBITDA | -32.50M |
| EBIT | -32.73M |
| Earnings Per Share (EPS) | -$0.94 |
Balance Sheet
The company has $30.35 million in cash and $8.42 million in debt, giving a net cash position of $21.93 million or $0.36 per share.
| Cash & Cash Equivalents | 30.35M |
| Total Debt | 8.42M |
| Net Cash | 21.93M |
| Net Cash Per Share | $0.36 |
| Equity (Book Value) | 18.93M |
| Book Value Per Share | 0.31 |
| Working Capital | 18.06M |
Cash Flow
| Operating Cash Flow | -35.23M |
| Capital Expenditures | n/a |
| Free Cash Flow | -35.23M |
| FCF Per Share | -$0.79 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
BioVie does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.82% |
| Shareholder Yield | -26.82% |
| Earnings Yield | -157.67% |
| FCF Yield | -149.39% |
Analyst Forecast
The average price target for BioVie is $6.33, which is 1,542.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $6.33 |
| Price Target Difference | 1,542.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on November 22, 2019. It was a reverse split with a ratio of 1:125.
| Last Split Date | Nov 22, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:125 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |